Alternating Hemiplegia of Childhood: Development of a Disease-Specific Clinical Rating Scale.
文献摘要
Background and objectives Alternating hemiplegia of childhood (AHC) is a rare neurodevelopmental disorder, primarily caused by pathogenic variants in ATP1A3 that account for approximately 80% of cases. It is characterized by both paroxysmal and chronic neurologic features. Currently, no validated, disease-specific clinical outcome measures exist for AHC, limiting standardized assessment and longitudinal tracking. We aimed to develop and validate the AHC Rating Scale (AHC-RS), a tool applicable across all age groups. We hypothesized that the AHC-RS would demonstrate strong inter-rater reliability and construct validity. Methods We conducted a multicenter observational study to assess the reliability and validity of the AHC-RS. Patients with clinically or genetically confirmed AHC-the sole inclusion criterion-were recruited from specialized neurology centers in Italy, Spain, and France. Each participant was visited following a standardized video protocol and evaluated independently by 4 trained neurologists using the AHC-RS. The primary outcome was inter-rater reliability, measured using the intraclass correlation coefficient (ICC). Construct validity was assessed through correlation with the Burke-Fahn-Marsden Dystonia Rating Scale. Results Forty-eight patients, 45.8% men and 54.2% women (median age: 18.6 years - SD: 12.4, range 2-48), were included. The AHC-RS evaluates 4 different domains: Paroxysmal Nonepileptic Manifestations, Epilepsy, Nonparoxysmal Manifestations, and Adaptive Capacities. Inter-rater reliability was excellent across all domains (ICC: 0.95-0.99). Construct validity was supported by a moderate correlation between the AHC-RS total score and the Burke-Fahn-Marsden Scale (Spearman rho = 0.58; 95% CI 0.29-0.78). A strong correlation was observed between the Nonparoxysmal Score and the Adaptive Score ( r = 0.74; 95% CI: 0.58-0.85), while the Paroxysmal Nonepileptic Score and Nonparoxysmal Score were not significantly associated. Discussion The AHC-RS shows excellent inter-rater reliability and good construct validity, supporting its use as a disease-specific outcome measure for AHC. These findings confirm clinical observations that paroxysmal and chronic symptoms may progress independently and highlight the greater impact of nonparoxysmal features on long-term functional outcomes. This scale offers a standardized tool for both clinical evaluation and future therapeutic trials. Further validation in larger and more diverse cohorts is warranted.